Huron (HURN) Q4 2025 earnings review
Margin Expansion Shines While Organic Growth Decelerates
Huron capped off FY25 with record Revenues Before Reimbursable Expenses (RBR) of $1.66 billion, but the surface-level Q4 revenue growth of 11.3% masks a sharp organic deceleration to 5.2% (down from 10.2% in Q3). The culprit is a sudden stall in the Education segment, which reversed into slightly negative territory (-0.1% YoY). However, management executed brilliantly on profitability: Adjusted EBITDA margin accelerated to 15.7% in Q4, up from 14.6% a year ago, fueled by incredible operating leverage in the Healthcare segment. While GAAP Net Income fell 10% YoY due to acquisition remeasurement charges, Adjusted EPS surged 14%. The 2026 guidance projects steady, slightly decelerating top-line growth but continued margin expansion, supported by a newly increased $900M share repurchase authorization.
🐂 Bull Case
Adjusted EBITDA margins are expanding reliably, reaching 15.7% in Q4. Healthcare operating margins achieved a staggering 32.4%, proving that Huron's integrated service delivery model is generating significant operating leverage.
Huron actively returns cash to shareholders, repurchasing 6.6% of its outstanding stock in 2025 for $166.2M. The board just authorized an increase to the buyback program from $700M to $900M, providing a massive floor for the stock.
🐻 Bear Case
Reported Q4 growth of 11.3% was heavily inflated by $27.3M from recent acquisitions. Stripping this out, organic RBR growth decelerated sharply to 5.2%, down from 10.2% in Q3 and 7.1% for the full year.
After consistent mid-to-high single-digit growth throughout early 2025, the Education segment reversed trend in Q4, shrinking 0.1% YoY. This exposes vulnerability in a segment that comprises 30% of total company revenue.
⚖️ Verdict: ⚪
Neutral. The profitability metrics are outstanding, and the aggressive buyback program provides excellent downside protection. However, the abrupt deceleration in organic growth and the sudden stall in the Education segment warrant caution before fully buying into the multi-year growth narrative.
Key Themes
Healthcare Margins Reaching New Heights
Healthcare continues to be the company's profit engine. While RBR growth decelerated from 19.9% in Q3 to 9.6% in Q4, operating margin accelerated dramatically, expanding 210 basis points YoY to reach 32.4%. This indicates that the larger, integrated strategy and performance improvement engagements secured earlier in the year are scaling highly efficiently.
Education Segment Reversing to Contraction
A notable break in trend occurred in the Education segment, which accounts for 30% of total RBR. After growing 10%, 5.3%, and 6.9% in Q1, Q2, and Q3 respectively, Q4 RBR reversed to -0.1% YoY ($118.7M vs $118.8M). This contradicts previous management optimism regarding record sales conversions and steady digital transformation demand in higher education.
M&A Masking Commercial Weakness
The Commercial segment posted a massive 36.6% YoY RBR growth rate in Q4, accelerating from Q3. However, this is largely inorganic. The company completed acquisitions (including Treliant and AXIA) that added $27.3M of incremental revenue company-wide in Q4. Commercial operating margins recovered to 20.0% (up from a dismal 15.4% in Q3), showing early signs that integration costs are fading, but true organic demand in strategy and financial advisory remains clouded by the M&A numbers.
Net Income Impacted by Contingency Charges
GAAP Net Income reversed trend, dropping 10% YoY in Q4 to $30.7M. This was driven by a $2.2M contingent consideration remeasurement charge related to recent acquisitions, compared to a $2.4M divestiture gain in the prior year. While adjusted metrics filter this out, it highlights the messy GAAP earnings profile generated by an aggressive programmatic M&A strategy.
AI and Digital Modernization
Management continues to publish supplemental materials outlining how artificial intelligence is driving demand. Utilization in the Digital capability accelerated to 79.7% in Q4 (up from 77.7% a year ago), indicating that client appetite for ERP implementations and data foundation projects—precursors for AI deployment—remains robust across all segments.
Other KPIs
Stable. Up slightly from 77.2% in 24Q4. This indicates that the aggressive hiring management undertook mid-year (which pressured Q1 and Q3 utilization) has successfully been absorbed by billable projects.
Accelerating. Up 46.3% YoY from 1,530 at the end of 2024. This massive headcount expansion represents a structural mix shift toward recurring revenue managed services, specifically within the Healthcare segment (which accounts for 2,117 of these professionals).
In 2025, Huron bought back 1.2 million shares, representing 6.6% of outstanding stock. In Q4, the board dramatically increased the buyback authorization from $700M to $900M, signaling high conviction in future free cash flow generation.
Guidance
Decelerating. The midpoint of $1.82B implies 9.5% YoY growth, a step down from the 11.9% growth achieved in 2025. This likely reflects a full-year organic growth rate stabilizing in the mid-single digits as acquisition comparables roll over.
Accelerating. Improving from the 14.3% reported for FY25. This shows management's commitment to marching toward their long-term 'mid-teen' margin goals through pricing discipline and internal efficiencies.
Decelerating. The midpoint of $8.75 implies an 11.7% YoY growth rate. While healthy, this is a deceleration from the 21.0% EPS growth delivered in FY25, partially due to tougher base effects.
Key Questions
Education Segment Stagnation
Education RBR was completely flat YoY in Q4 after growing nicely in prior quarters. Was this driven by project timing, a pullback in client IT budgets, or regulatory caution? What is embedded in the 2026 guidance for this segment?
Organic vs Inorganic Growth
Organic growth slowed to 5.2% this quarter. How much of the 9.5% implied revenue growth for 2026 is expected to come from organic consulting demand versus the wrap-around effects of 2025 acquisitions like Treliant and AXIA?
M&A Integration Costs
Contingent consideration remeasurement charges dragged down GAAP Net Income in Q4. Are there remaining integration costs or earn-out liabilities from the Treliant or AXIA deals that will impact cash flow or GAAP earnings in early 2026?